Company Overview and News

Encounter Resources raises $2.75 million to advance its projects in Western Australia

Encounter Resources Ltd (ASX:ENR) has received firm placement commitments from professional and sophisticated investors to raise about $2.75 million at 6 cents per share.

Newcrest builds Tanami presence in search of gold discoveries

Newcrest Mining and ABM Resources will together advance exploration of the Euro gold project in the Tanami in Northern Territory after signing an agreement.

Newcrest executes five JVs with Encounter

Newcrest Mining and Encounter Resources have formed a series of exploration joint ventures in Western Australia as a result of a project generation alliance established between the companies last year.

Newcrest expands Encounter exploration alliance

Newcrest Mining is assessing two new exploration opportunities with Encounter Resources as part of their project generation alliance.

Peel Mining substantial shareholder lifts stake, shares surge to 12-month high

Peel Mining Ltd’s (ASX:PEX) substantial shareholder Hampton Hill Mining NL (ASX:HHM) and associates have shown confidence in the company by lifting their combined interest to 19.3% from 18.25%.

Encounter Resources bags $2.9M to advance gold projects

Encounter Resources (ASX:ENR) has received firm placement commitments from professional and sophisticated investors to raise circa $2.9 million at $0.10 per share.

Encounter Resources to lift cash position after gold discovery

Encounter Resources (ASX:ENR) has been granted a trading halt by the ASX, pending details of a capital raising.

Encounter Resources reveals gold anomaly near Telfer mine

Encounter Resources (ASX:ENR) has confirmed a high-grade gold exploration opportunity following the review of historical exploration data at the East Thomson’s Dome project in Western Australia.

Encounter Resources drill results suggests more gold to come

Telfer West covers an area of about 121 square kilometres and is located 25 kilometres northwest of Newcrest Mining’s (ASX:NCM) major gold-copper operation at Telfer.

Encounter Resources Ltd pursuing gold targets at Telfer West

The company holds over 2000 square kilometres of tenure in the Paterson Province, exploring copper, cobalt and zinc-lead deposits at Yeneena as well as gold-copper deposits in the Telfer region. This is the first drilling at Telfer West, located 25 kilometres north-west of Newcrest Mining Ltd’s (ASX:NCM) major gold-copper operation, since 1991. The drilling at Telfer West will initially focus on continuing the prior drill testing at the Egg Prospect and a north-west trending magnetic anomaly.

Encounter Resources Ltd begins drilling at Millennium Zinc Prospect

Encounter Resources Ltd (ASX:ENR) has commenced a diamond drilling program at the Millennium Zinc Prospect in the Yeneena Region of Western Australia. Encounter is also planning to drill the Lookout Rocks Copper Prospect, Aria IOCG Prospect, BM1-BM7 Copper Prospect and the Telfer West Gold Project in the coming months. The Millennium Zinc Prospect is located in the northeast of Yeneena and is subject to an earn-in agreement with Hampton Hill Mining NL (ASX:HHM).

Encounter Resources Ltd begins drilling at Millennium Zinc Prospect

Encounter Resources Ltd (ASX:ENR) is a greenfields exploration company. Its flagship project is the Yeneena project located in the Paterson Province of Western Australia.

Sulphur could hold key in search for future mines

It is unlikely many people see sulphur as the answer to the question of where to find gold nuggets.

Encounter starts Millennium drilling

JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

Encounter starts Millennium drilling

JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...